Orexo, a Swedish pharmaceutical company, has decided to stop pursuing an app for treating depression called Deprexis. The company had been struggling to sell the product and announced that it will no longer license it from the German manufacturer GAIA. This decision comes after years of working on Deprexis in the United States and having deals for other apps like Modia. Despite the recent creation of a pathway for digital mental health treatments to get paid by Medicare, Orexo chose to pull the plug on Deprexis, citing difficulties with reimbursement for digital therapeutics in the U.S.
Source link
Why Orexo is abandoning a digital therapeutic for depression
